Examlex
Recently, two follow-up studies of mortality among licensed pesticide applicators were published in the occupational health literature. One study from Florida found an overall standardized mortality ratio (SMR) of 1.80 and excess deaths due to leukemia, cancers of the brain, and lung cancer. A second study, based in Iowa, found an overall SMR of 1.20 and an elevated SMR for lung cancer only. The mortality statistics for the respective states were used for comparison purposes.
A. Is there reason for concern? Why or why not?
B. Why do you think that there was an elevated SMR for only one specific cause of death in Iowa? Knowing that applicators in both states use similar chemicals in their work, do you think that pesticide workers in Florida should be concerned that they may be at higher risk than their colleagues in Iowa?
Lengel-Daft Contingency Model
A framework suggesting that the effectiveness of information processing and communication in organizations depends on the fit between the complexity of the task and the information richness.
Lean Medium
A method or tool that facilitates efficient and effective communication or project management with minimal waste.
Lengel-Daft Contingency Model
A theoretical framework suggesting that the effectiveness of communication processes and mediums varies according to the uncertainty and complexity of the situation.
Rich Medium
Communication channels with the capacity to convey messages in a more understanding and effective manner through immediate feedback, multiple cues, and personalization.
Q3: Across the United States, using data from
Q6: The U.S. Court of Appeals decision that
Q11: High rates of mortality from hypertension found
Q17: Across the United States, using data from
Q19: In less developed regions, triangular population distributions
Q26: High firearm death rates and homicide rates
Q26: According to the Centers for Disease Control
Q28: The Stanford Five-City Project, a major community
Q30: Using epidemiology for operational research involves the
Q32: Surrogate endpoints for a clinical trial of